What the change means for most adults
Aspirin is no longer recommended for routine primary prevention of cardiovascular disease in otherwise healthy adults. Major guidelines now emphasize that the bleeding risk in many people outweighs the potential benefit for preventing a first heart attack or stroke. This shift reflects more recent evidence and a move toward personalized decisions based on individual risk and shared discussion with a clinician. The change does not apply to people already taking aspirin for secondary prevention after a confirmed cardiovascular event, nor to select higher-risk situations where benefit still clearly outweighs harm.
Aspirin in cardiovascular prevention: background and context
For decades, low-dose aspirin was routinely suggested to lower the risk of first heart attacks and strokes. More recent trials, notably the ASPREE trial in older adults, found that for healthy older people, the risk of serious bleeding with daily aspirin was approximately balanced with any cardiovascular prevention benefit. As a result, organizations such as the U.S. Preventive Services Task Force now recommend against initiating aspirin for primary prevention in many adults, particularly those age 60 and older. The emphasis has moved toward risk assessment, lifestyle optimization, and control of conditions such as high blood pressure and cholesterol, which often provide greater net benefit than aspirin for preventing a first event.
Key guideline updates
Guidelines evolve as new data emerge. The latest guidance consolidates evidence from randomized trials and observational studies to clarify where aspirin offers net benefit. For primary prevention, routine use is generally not recommended in adults with low or moderate bleeding risk, while selective use may be considered in carefully selected higher-risk individuals after a clinician–patient discussion. For secondary prevention, which follows a prior heart attack, stroke, or stent, aspirin remains a well-established therapy unless contraindicated. The overarching message is that one-size-fits-all recommendations are no longer appropriate; decisions should be tailored and discussed with a healthcare provider.
Who may still benefit from aspirin
Certain people may still derive a net benefit from continuing or starting aspirin under medical supervision. This generally includes adults at higher net cardiovascular risk, where the predicted risk of a heart attack or stroke outweighs bleeding risk. For example, in some younger adults with multiple traditional risk factors or those with certain inherited thrombophilias, the balance may favor aspirin. The decision is individualized and considers factors such as blood pressure control, smoking status, diabetes, age, and bleeding risk. If you are unsure whether you fall into this group, bring this question to your clinician with your personal risk profile.
Guideline-aligned considerations for use
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Primary prevention in healthy adults aged 60+ | Generally not recommended due to bleeding risk outweighing potential benefit | Guideline (USPSTF, ACC/AHA aligned) |
| Secondary prevention after cardiovascular event | Recommended unless contraindicated (e.g., allergy, active bleeding) | Strong evidence, multiple trials |
| Select higher-risk primary prevention | May be considered after clinician–patient risk discussion; individualized | Guideline (ages and risk-dependent) |
| Age-related bleeding risk | Increases with age; a key reason to avoid routine use in older adults | Consistent trial data (e.g., ASPREE) |
Practical risks and benefits of daily low-dose aspirin
Low-dose aspirin reduces platelet aggregation, which lowers the chance of clots that cause heart attacks and strokes. However, this same effect raises the risk of bleeding, including gastrointestinal and intracranial hemorrhage. For many healthy adults, the small absolute benefit in preventing a first event does not justify that bleeding risk, especially when safer measures—such as controlling blood pressure, managing cholesterol, not smoking, and maintaining a healthy diet and activity level—are in place. If you are already taking aspirin for primary prevention, do not stop on your own; discuss the benefits and risks with your clinician to decide whether continuation is appropriate for your situation.
Balancing benefits and harms: concise overview
- Benefit: modest reduction in first heart attack and ischemic stroke in some higher-net-risk individuals
- Risk: increased bleeding, including serious gastrointestinal and intracranial events
- Context: benefit is greatest when baseline cardiovascular risk is elevated and bleeding risk is low
- Monitoring: control of blood pressure and avoidance of other bleeding-risk medications (e.g., NSAIDs) can lower harm
- Shared decision-making: discuss personal risk profile, preferences, and alternatives with your clinician
When aspirin remains an important therapy
Even with updated guidance against routine primary prevention, aspirin has a well-established role in secondary prevention. After a heart attack, stroke, or certain revascularization procedures, aspirin (often combined with another antiplatelet in dual antiplatelet therapy for a defined period) significantly reduces the risk of recurrent events. People with certain conditions, such as mechanical heart valves or selected high-risk coronary syndromes, may also be advised to continue aspirin. The key is matching the right therapy to the right patient at the right time, based on clear clinical indications and informed discussion.
Clinical scenarios where aspirin is typically recommended
| Scenario | Status | Notes |
|---|---|---|
| Prior myocardial infarction or ischemic stroke | Recommended (unless contraindicated) | Well-supported by extensive evidence |
| Stable coronary artery disease or prior stent | Recommended, often as part of dual antiplatelet therapy for a period | Duration depends on guideline and clinical context |
| Mechanical heart valve | Often recommended, sometimes with anticoagulation | Individualized based on valve type and risk |
| High bleeding risk or peptic ulcer disease | Generally avoided or used with gastroprotection | Bleeding risk may outweigh benefit |
Steps to take if you’re currently taking aspirin for prevention
If you are taking daily aspirin to prevent a first heart attack or stroke and have not had a cardiovascular event, do not stop without medical advice. Schedule a discussion with your clinician to review your personal risk factors, including age, blood pressure, cholesterol, diabetes, smoking status, and bleeding history. Together, you can weigh the potential benefit against the risk of bleeding and decide whether to continue, adjust, or stop aspirin. If your clinician recommends discontinuation, they will advise on safe cessation and alternative prevention strategies, which may include optimizing blood pressure, statin therapy, lifestyle changes, and, when appropriate, managing other modifiable risk factors.
Action checklist for patients
- Review personal cardiovascular and bleeding risk with your clinician
- Confirm whether you are on aspirin for primary or secondary prevention
- Discuss age, blood pressure, diabetes, smoking, and concurrent medications
- Plan follow-up tests and monitoring if continuation is chosen
- Explore non-aspirin prevention strategies (blood pressure control, statins, lifestyle)
Emerging evidence and future directions
Research on antiplatelet strategies continues to refine recommendations. Trials and real-world data are exploring who truly derives net benefit from aspirin in contemporary practice, including the roles of newer risk scores, imaging to detect subclinical atherosclerosis, and tailored antithrombotic approaches. As evidence evolves, guidance will reflect the most current balance of benefit and harm. For now, individualized decision-making and shared clinician–patient discussion are central to the responsible use of aspirin for prevention.